Phase

Immunis Inc. is a private biotechnology company recruiting participants between the ages of 50-75 with muscle atrophy related to knee osteoarthritis f.

For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: [www.immunisbiomedical.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunisbiomedical.com&esheet=53289655&newsitemid=20230124005423&lan=en-US&anchor=www.immunisbiomedical.com&index=7&md5=d64bbaf099314a33b40bb2afbccfde5b) Immunis’ investigational secretome product is injected into the quadriceps muscles, with the ultimate goal of alleviating the knee pain and stiffness for individuals with knee osteoarthritis, and the need for associated surgeries. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. Up to 18 patients will be enrolled in the trial and randomly assigned to an IMM01-STEM dose cohort. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. For additional information about Immunis’ trial participant qualifications, please visit: [www.immunisbiomedical.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.immunisbiomedical.com&esheet=53289655&newsitemid=20230124005423&lan=en-US&anchor=www.immunisbiomedical.com&index=5&md5=0db120ef3078c4310a54f12b72f80205) This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. [Phase 1/2a clinical trial](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05211986&esheet=53289655&newsitemid=20230124005423&lan=en-US&anchor=Phase+1%2F2a+clinical+trial&index=4&md5=1d757b04ff88cb86b4ada756a7d1e896) is an open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in elderly participants with muscle atrophy associated with knee osteoarthritis (KOA). Treatment will be administered in the form of intramuscular injections twice a week, for four weeks (8 injections total). [BUSINESS WIRE](https://www.businesswire.com/))-- [Immunis Inc.](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fimmunisbiomedical.com%2F&esheet=53289655&newsitemid=20230124005423&lan=en-US&anchor=Immunis+Inc.&index=1&md5=178b0adb2ba2446c7bab069184de7fd1) is a private biotechnology company recruiting participants between the ages of 50-75 with muscle atrophy related to knee osteoarthritis for its [Phase 1/2a clinical trial.](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05211986&esheet=53289655&newsitemid=20230124005423&lan=en-US&anchor=Phase+1%2F2a+clinical+trial.&index=2&md5=2b729cea206bc2dbfe6387bfcb8fc193) The trial will assess the safety and tolerability of Immunis’ investigational secretome product designed to benefit immune system modulation and health. There are currently no treatments to attenuate muscle loss or to enhance muscle regeneration.

The New Communications Minister Plans to Shut Israel's Public Broadcaster Among Other Media Authorities and Supervisory Bodies The New Government Also Aims ...

If all the plans of Netanyahu, Karhi and Bismuth are realized, the media will be damaged in all arenas. Bismuth’s bill, which Karhi signed by the way, reflects a new phase in Netanyahu’s efforts to destroy freedom of expression and the pursuit of truth. We wanted to ask Bismuth whether recordings such as the “Lying son of a liar” quip could be published after the law is enacted. The bill would prohibit the release of a recording that includes “sensitive information” as defined in the Privacy Protection Law. Netanyahu and his partners are doing all they can to guarantee that a recording like this will never be broadcast again; one of their ploys is the egregious move to shutter the public broadcaster. It challenged his standing and the unity of his bloc.

By Colin Kellaher Finch Therapeutics Group Inc. on Tuesday said it is ending a late-stage study of its lead drug candidate and dismissing most of its staff, ...

The Somerville, Mass., company said it is cutting 77 full-time positions, or 95% of its workforce, with the bulk of the jobs ending in February. Finch Therapeutics Group Inc. on Tuesday said it is ending a late-stage study of its lead drug candidate and dismissing most of its staff, as the clinical-stage microbiome therapeutics company plans to focus on realizing the value of its intellectual-property estate and other assets.

Memo Therapeutics announced positive Phase 1 data with AntiBKV, an antibody targeting BK polyomavirus infection in renal transplant patients.

MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. There is currently no disease modifying therapy available to treat BKV infection except for the lowering of immunosuppression. “AntiBKV has the potential to be a best- and first-in-class antibody for the treatment of BKV infection in kidney transplant recipients. With 50,000 kidney transplant procedures carried out in the US and Europe alone, AntiBKV addresses a large and rapidly growing market, with an estimated size well beyond USD 1 billion,” said Dr. We believe that AntiBKV, with its 100x more potent neutralization capacity than benchmark antibodies, if confirmed in clinical studies, could present a game-changer for patients who are currently seriously underserved,” said Dr. “This initial clinical data for AntiBKV is very encouraging.

Additionally, Finch has pre-clinical microbiome assets that are designed to target ulcerative colitis, Crohn's disease, and autism spectrum disorder. Finch has ...

The second phase of the State government's anti-drug campaign will end with the 'Lahariyilla Theruvu' programme on Thursday, Minister for Excise M.B. Rajesh ...

The maximum goals scored as part of the goal challenge was in Malappuram district – 28,30,063. He appealed to the people to come forward to make the ‘Lahariyilla Theruvu’ programme to be held at district centres on Thursday a success. The State government had earlier organised a football “goal challenge” to fight drugs as part of ‘No to drugs’ campaign.

The first phase involves the development of 1,116 dunums of the estate's total 4,700 dunums, and the construction of industrial buildings on 22,000 square ...

This particular project is characterised by its strategic location close to international roads on boarders with Iraq, Syria and Saudi Arabia, making it a focus of interest and attraction for investors. The first phase also involves solely construction work, such as construction of industrial buildings, the implementation of water, electricity, communications, street lighting and fire fighting infrastructure, as well as the construction of the estate’s administrative buildings, which include on its sides service buildings and water tanks, Juwaid said. The first phase involves the development of 1,116 dunums of the estate’s total 4,700 dunums, and the construction of industrial buildings on 22,000 square metres of land with a total cost of JD21 million, the Jordan News Agency, Petra, reported.